Sarah‐Jane Dawson

23.4k total citations · 5 hit papers
80 papers, 7.1k citations indexed

About

Sarah‐Jane Dawson is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarah‐Jane Dawson has authored 80 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Cancer Research, 45 papers in Oncology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarah‐Jane Dawson's work include Cancer Genomics and Diagnostics (41 papers), Cancer Cells and Metastasis (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Sarah‐Jane Dawson is often cited by papers focused on Cancer Genomics and Diagnostics (41 papers), Cancer Cells and Metastasis (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Sarah‐Jane Dawson collaborates with scholars based in Australia, United Kingdom and United States. Sarah‐Jane Dawson's co-authors include Carlos Caldas, Nitzan Rosenfeld, Dana W.Y. Tsui, Davina Gale, Tim Forshew, Muhammed Murtaza, Suet‐Feung Chin, Sean Humphray, David Bentley and Mark A. Dawson and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Communications.

In The Last Decade

Sarah‐Jane Dawson

78 papers receiving 7.0k citations

Hit Papers

Analysis of Circulating Tumor DNA to Monitor Metastatic B... 2012 2026 2016 2021 2013 2013 2012 2020 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
    2013 1.6k citations Sarah‐Jane Dawson, Oscar M. Rueda et al. profile →
  2. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
    2013 1.2k citations Sarah‐Jane Dawson, Carlos Caldas et al. profile →
  3. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
    2012 975 citations Sarah‐Jane Dawson, Carlos Caldas et al. profile →
  4. Non-genetic mechanisms of therapeutic resistance in cancer
    2020 353 citations Jean‐Christophe Marine, Sarah‐Jane Dawson et al. Nature reviews. Cancer profile →
  5. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. profile →

Peers

Sarah‐Jane Dawson
Tim Forshew United Kingdom
Steve Szabo United States
Gottfried E. Konecny United States
Charlotte K.Y. Ng Switzerland
François‐Clément Bidard France
Michail Ignatiadis Belgium
Michael Bilous Australia
Martin Filipits Austria
Lukas C. Amler United States
Ryan B. Corcoran United States
Tim Forshew United Kingdom
Sarah‐Jane Dawson
Citations per year, relative to Sarah‐Jane Dawson Sarah‐Jane Dawson (= 1×) peers Tim Forshew

Countries citing papers authored by Sarah‐Jane Dawson

Since Specialization
Citations

This map shows the geographic impact of Sarah‐Jane Dawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah‐Jane Dawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah‐Jane Dawson more than expected).

Fields of papers citing papers by Sarah‐Jane Dawson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah‐Jane Dawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah‐Jane Dawson. The network helps show where Sarah‐Jane Dawson may publish in the future.

Co-authorship network of co-authors of Sarah‐Jane Dawson

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah‐Jane Dawson. A scholar is included among the top collaborators of Sarah‐Jane Dawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah‐Jane Dawson. Sarah‐Jane Dawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations
2.
3.
Siva, Shankar, Mathias Bressel, Ross Jennens, et al.. (2023). SABRSeq: A Randomized Phase Ib Trial of SABR Sequencing with Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics. 117(2). e58–e58. 4 indexed citations
4.
Lee, Rebecca, Dominic G. Rothwell, Richard A. Jackson, et al.. (2023). P56 Trial redesign for the phase II/III DETECTION trial: circulating tumour DNA-guided therapy for stage IIB/C melanoma after surgical resection. British Journal of Dermatology. 188(Supplement_4). 1 indexed citations
5.
Savas, Peter, Stephen J. Luen, Elizabeth F. Blackley, et al.. (2022). Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discovery. 12(9). 2058–2073. 38 indexed citations
6.
7.
Murray, N., Prudence A. Francis, Nicholas Zdenkowski, et al.. (2022). 91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial. Annals of Oncology. 33. S164–S165. 2 indexed citations
8.
Lee, Jenny, Alexander M. Menzies, Matteo S. Carlino, et al.. (2020). Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(15). 4064–4071. 62 indexed citations
9.
Marine, Jean‐Christophe, Sarah‐Jane Dawson, & Mark A. Dawson. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nature reviews. Cancer. 20(12). 743–756. 353 indexed citations breakdown →
10.
Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2019). Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood. 134(Supplement_1). 756–756. 25 indexed citations
11.
Dawson, Sarah‐Jane. (2018). Characterizing the Cancer Genome in Blood. Cold Spring Harbor Perspectives in Medicine. 9(4). a026880–a026880. 8 indexed citations
12.
Wong, Stephen Q., Richard W. Tothill, Sarah‐Jane Dawson, & Rodney J. Hicks. (2017). Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. Journal of Nuclear Medicine. 58(6). 869–870. 3 indexed citations
13.
Savas, Peter, Zhi L. Teo, Christophe Lefèvre, et al.. (2016). The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”. PLoS Medicine. 13(12). e1002204–e1002204. 83 indexed citations
14.
Tam, Constantine S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2016). The combination of ibrutinib and venetoclax (ABT-199) rapidly achieves complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study. Haematologica. 3 indexed citations
15.
Blows, Fiona M., H. Raza Ali, Sarah‐Jane Dawson, et al.. (2015). Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. Applied immunohistochemistry & molecular morphology. 24(3). 221–226. 9 indexed citations
16.
Dawson, Sarah‐Jane, Oscar M. Rueda, Samuel Aparício, & Carlos Caldas. (2013). A new genome‐driven integrated classification of breast cancer and its implications. The EMBO Journal. 32(5). 617–628. 207 indexed citations
17.
Ali, H. Raza, Sarah‐Jane Dawson, Fiona M. Blows, et al.. (2011). Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Research. 13(6). R118–R118. 89 indexed citations
18.
Dawson, Sarah‐Jane, Nikita Makretsov, Fiona M. Blows, et al.. (2010). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British Journal of Cancer. 103(5). 668–675. 257 indexed citations
19.
Dawson, Sarah‐Jane, Rodney J. Hicks, David G. Allen, et al.. (2009). Intraperitoneal distribution imaging in ovarian cancer patients. Internal Medicine Journal. 41(2). 167–171. 5 indexed citations
20.
Dawson, Sarah‐Jane, et al.. (1991). ALLELE SPECIFIC DIFFERENTIAL BINDING OF HEPG2 NUCLEAR EXTRACTS TO A COMMON POLYMORPHISM IN THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) PROMOTER WHICH IS ASSOCIATED WITH ALTERED PLASMA PAI-1 LEVELS. UCL Discovery (University College London). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Forshew Breakdown of academic impact, for papers by Steve Szabo Breakdown of academic impact, for papers by Gottfried E. Konecny Breakdown of academic impact, for papers by Charlotte K.Y. Ng Breakdown of academic impact, for papers by François‐Clément Bidard Breakdown of academic impact, for papers by Michail Ignatiadis Breakdown of academic impact, for papers by Michael Bilous Breakdown of academic impact, for papers by Martin Filipits Breakdown of academic impact, for papers by Lukas C. Amler Breakdown of academic impact, for papers by Ryan B. Corcoran
Rankless by CCL
2026